Symeonidis A And Immune Function Parameters

1. Manusow D, Weinerman BH, Hisada M, et al. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975;232:267-269.

2. Hisada M, Biggar RJ, Greene MH, Fraumeni JF, Jr., Travis LB. Solid tumors after chronic lymphocytic leukemia. Blood 2001;98:1979-1981.

3. Rozman C, Montserrat E, Vinolas N. Serum immunoglobulins in B-CLL: natural history and prognostic significance. Cancer 1988;61:279-283.

4. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057.

5. Shaw R, Szwed C, Boggs D. Infection and immunity in chronic lymphocytic leukemia. Arch Intern Med 1960; 106:467-477.

6. Twomey J. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 1973; 132:562-565.

7. Hartkamp A, Mulder A, Rijkers G. Antibody responses to pneumococcal and hemophilus vaccinations in patients with B-cell chronic lymphocytic leukemia. Vaccine 2001;19:1671-1677.

8. Sampalo A, Navas G, Medina F, Segundo C, Camara C, Brieva JA. Chronic lymphocytic leukemia B-cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction. Blood 2000; 96:3168-3174.

9. Kipps T, Carson D. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993;81:2475-2487.

10. Hamblin T, Oscier D, Young B. Autoimmunity in chronic lymphocytic leukemia. J Clin Pathol 1986;39:713-716.

11. Kay N. Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood 1981;57:418-420.

12. Kay NE, Perri RT. Immunobiology of malignant B-cells and immunoregulatory cells in B-chronic lymphocytic leukemia. Clin Lab Med 1988;8:163-177.

13. Kay N, Zarling J. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984;63:305-309.

14. Caligaris-Cappio F, Gobbi M, Bofill M. Infrequent normal B-lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med 1982;155:623-628.

15. Hashimoto S, Dono M, Watai M. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+, CD5+ chronic lymphocytic leukemia B-cells. J Exp Med 1995;181:1507-1517.

16. Panayiotidis P, Ganeshaguru K, Dforoni L, Hoffbrand A. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 1995;9:1227.

17. Tinhofer I, Marschitz I, Kos M, et al. Differential sensitivity of CD4+ and CD8+ T-lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 1998;91:4273-4281.

18. Conrad D, Waldschmidt T, Lee W, et al. Effect of B cell stimulatory factor-1 (interleukin 4) on Fc epsilon and Fc gamma receptor expression on murine B-lymphocytes and B cell lines. J Immunol 1987;139:2290-2296.

19. Knauf WU, Langenmayer I, Ehlers B, et al. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymph 1997;27:523-532.

20. Sarfati M. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88:4259-4264.

21. Liu Y, Cairns J, Holder M, et al. Recombinant 25-kDa CD23 and interleukin 1 alpha promote the survival of germinal center B-cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol 1991;21:1107-1114.

22. Mossalayi M, Arock M, Bertho J, et al. Proliferation of early human myeloid precursors induced by interleukin-1 and recombinant soluble CD23. Blood 1990;75:1924-1927.

23. Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY. CD21 is a ligand for CD23 and regulates IgE production. Nature 1992;358:505-507.

24. Dorfman DM, Schultze JL, Shahsafaei A, et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997;90:4297-4306.

25. Linsley P, Brady W, Grosmaire L, Aruffo A, Damle N, Ledbetter J. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173:721-730.

26. Schwartz R. Costimulation of lymphocyites: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-1068.

27. Eris J, Basten A, Brink R, Doherty K, Kehry M, Hodgkin P. Anergic self-reactive B-cells present self antigen and respond normally to CD40-dependent T-cell signals but are defective in antigen-receptor-mediated functions. Proc Natl Acad Sci USA 1994;91:4392-4396.

28. Ranheim E, Kipps T. Activated T-cells induce expression of B7/BB1 on normal or leukemic B-cells through a CD40-dependent signal. J Exp Med 1993;177:925-935.

29. Yellin M, Sinning J, Covey L, et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B-cells or chronic lymphocytic leukemia B-cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994;153:666-674.

30. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B-cells. J Clin Invest 1998;101:1133-1141.

31. Ranheim E, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B-cells. Blood 1995;85:3556-3565.

32. Lotz M, Ranheim E, Kipps T. Transforming growth factor beta as endogenous growth inhibitor of chronic lym-phocytic leukemia B-cells. J Exp Med 1994;179:999-1004.

33. Zaknoen S, Kay N. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Review 1990;4:165-174.

34. Farace F, Orlanducci F, Dietrich P, et al. T cell repertoire in patients with B chronic lymphocytic leukemia: evidence for multiple in vivo T cell clonal expansions. J Immunol 1994;153:4281-4290.

35. Wen T, Mellstedt H, Jondal M. Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. J Exp Med 1990;171:659-666.

36. Rezvany M-R, Jeddi-Tehrani M, Osterborg A, Kimby E, Wigzell H, Mellstedt H. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood 1999;94:1063-1069.

37. Serrano D, Monteiro J, Allen S, et al. Clonal expansion within the CD4+ CD57+ and CD8+ CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol 1997;158:1482-1489.

38. Goolsby CL, Kuchnio M, Finn WG, Peterson L. Expansions of clonal and oligoclonal T-cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3+CD8+ T-cell population. Cytometry 2000;42:188-195.

39. Mu X, Kay NE, Gosland MP, Jennings CD. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T-cells. Br J Haematol 1997;96:733-735.

40. de Totero D, Reato G, Mauro F, et al. IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukemia. Br J Haematol 1999;104:589-599.

41. Kay NE, Han L, Bone ND, Williams G. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B-cells and blood CD8+ T-cells from B-CLL patients: impact on clonal B-cell apoptosis. Br J Hematol 2001;112:760-767.

42. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B-cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992;176:1319-1326.

43. Mainou-Fowler T, Craig V, Copplestone J, Hamon M, Prentice A. Effect of anti-APO1 on spontaneous apoptosis of B-cells in chronic lymphocytic leukaemia: the role of bcl-2 and interleukin 4. Leuk Lymph 1995;19:301-308.

44. Mainou-Fowler T, Copplestone J, Prentice A. Effect of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells. J Clin Pathol 1995;48:482-487.

45. Huang R, Tsuda H, Takatsuki K. Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells. Int J Hematol 1993;58:83-92.

46. Buschle M, Campana D, Carding S, Richard C, Hoffbrand A, Brenner M. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993;177:213-218.

47. Mainou-Fowler T, Craig V, Copplestone J, Hamon M, Prentice A. Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression and is inhibited by IL-4. Blood 1994;84:2297-2304.

48. Fluckiger A, Durand I, Banchereau J. Interleukin 10 induces apoptotic cell death lymphocytic leukemia cells. J Exp Med 1994;179:91-99.

49. Foa R, Massaia M, Cardona S, et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 1990;76:393-400.

50. Mainou-Fowler T, Miller S, Proctor SJ, Dickinson AM. The levels of TNF-a, IL-4 and IL-10 production by T-cells in B-cell chronic lymphocytic leukemia (B-CLL). Leuk Res 2001;25:157-163.

51. Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation/interaction markers on peripheral blood T-cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br J Hematol 2001;112:959-964.

52. Kaleem Z, White G, Zutter MM. Aberrant expression of T-cell associated antigens on B-cell non-Hodgkin lymphomas. Am J Clin Pathol 2001;115:396-403.

53. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4+CD25+ T-cells with regulatory properties from human blood. J Exp Med 2001;193:1303-1310.

54. Vuillier F, Tortevoye P, Binet JL, Dighiero G. CD4, CD8 and NK subsets in B-CLL. Nouv Rev Fr Hematol 1988; 30:331-334.

55. Apostolopoulos A, Symeonidis A, Zoumbos N. Prognostic significance of immune function parameters in patients with chronic lymphocytic leukaemia. Eur J Haematol 1990;44:39-44.

56. Frolova E, Richards S, Jones R, et al. Immunophenotypic and DNA genotypic analysis of T-cell and NK-cell subpopulations in patients with B-cell chronic lymphocytic leukaemia (B-CLL). Leuk Lymph 1995;16:307-318.

57. Ziegler H, Kay NE, Zarling J. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981;27:321-327.

58. Alvarez de Mon M, Casas J, Laguna R, Toribio M, deLandazuri M, Durantez A. Lymphokine induction of NK-like cytotoxicity in T-cells from B-CLL. Blood 1986;67:228-232.

59. Katrinakis G, Kyriakou D, Papadaki H, Kalokyri I, Markidou F, Eliopoulos G. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematol 1996;96:16-23.

60. Gunzer M, Janich S, Varga G, Grabbe S. Dendritic cells and tumor immunity. Semin Immunol 2001;13:291-302.

61. Bleijs DA, Geijtenbeek TB, Figdor CG, van Kooyk Y. DC-SIGN and LFA-1: a battle for ligand. Trends Immunol 2001;22:457-463.

62. Vuillier F, Maloum K, Thomas E, Jouanne C, Dighiero G, Scott-Algara D. Monocyte-derived dendritic cells from CLL patients display normal phenotypic and functional properties but spontaneously secrete IL-10. Blood 2001;98: 287b.

63. Chilosi M, Pizzolo G, Caligaris-Cappio F, et al. Immunohistochemical demonstration of follicular dendritic cells in bone marrow involvement of B-cell chronic lymphocytic leukemia. Cancer 1985;56:328-332.

64. Stadelmeyer E, Grube R, Chraust S, Linkesch W, Strunk D. Alteration of dendritic cell function in B-CLL. Blood 2001;98:287b.

65. Orsini E, Chiaretti S, Mauro F, Guarini A, Foa R. Defective dendritic cell compartment in chronic lymphocytic leukemia patients. Blood 2001;98:731a.

How To Bolster Your Immune System

How To Bolster Your Immune System

All Natural Immune Boosters Proven To Fight Infection, Disease And More. Discover A Natural, Safe Effective Way To Boost Your Immune System Using Ingredients From Your Kitchen Cupboard. The only common sense, no holds barred guide to hit the market today no gimmicks, no pills, just old fashioned common sense remedies to cure colds, influenza, viral infections and more.

Get My Free Audio Book

Post a comment